Reproductive Epidemiology group, Murdoch Children's Research Institute, Flemington Rd, Parkville, VIC, Australia.
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia.
BMC Pediatr. 2021 Oct 11;21(1):447. doi: 10.1186/s12887-021-02809-7.
The implementation of genomic testing in pregnancy means that couples have access to more information about their child's genetic make-up before birth than ever before. One of the resulting challenges is the management of genetic variations with unclear clinical significance. This population-based study will help to close this critical knowledge gap through a multidisciplinary cohort study of children with and without genomic copy number variants (CNVs) diagnosed before birth. By comparing children with prenatally-ascertained CNVs to children without a CNV, we aim to (1) examine their developmental, social-emotional and health status; (2) measure the impact of prenatal diagnosis of a CNV on maternal perceptions of child health, behavior and development; and (3) determine the proportion of prenatally-ascertained CNVs of unknown or uncertain significance that are reclassified as benign or pathogenic after 2 or more years.
This study will establish and follow up a cohort of mother-child pairs who have had a prenatal diagnosis with a chromosomal microarray from 2013-2019 in the Australian state of Victoria. Children aged 12 months to 7 years will be assessed using validated, age-appropriate measures. The primary outcome measures will be the Wechsler Preschool and Primary Scale of Intelligence IV (WPSSI-IV) IQ score (2.5 to 7 year old's), the Ages and Stages Questionnaire (12-30 months old), and the Brief Infant- Toddler Social and Emotional Assessment (BITSEA) score. Clinical assessment by a pediatrician will also be performed. Secondary outcomes will be scores obtained from the: Vineland Adaptive Behavior Scale, Maternal Postnatal Attachment Questionnaire, the Vulnerable Child Scale, Profile of Mood States, Parent Sense of Competence Scale. A descriptive analysis of the reclassification rates of CNVs after ≥2 years will be performed.
This study protocol describes the first Australian cohort study following children after prenatal diagnostic testing with chromosomal microarray. It will provide long-term outcomes of fetal genomic variants to guide evidence-based pre-and postnatal care. This, in turn, will inform future efforts to mitigate the negative consequences of conveying genomic uncertainty during pregnancy.
ACTRN12620000446965p ; Registered on April 6, 2020.
基因组检测在妊娠中的实施意味着夫妇在孩子出生前就能获得比以往更多的有关其遗传构成的信息。由此产生的挑战之一是管理具有不明确临床意义的遗传变异。这项基于人群的研究将通过对出生前诊断出基因组拷贝数变异(CNV)的儿童和没有 CNV 的儿童进行多学科队列研究,帮助缩小这一关键知识差距。通过将产前确定的 CNV 儿童与没有 CNV 的儿童进行比较,我们旨在:(1)检查他们的发育、社会情感和健康状况;(2)测量产前诊断 CNV 对母亲对孩子健康、行为和发育的感知的影响;(3)确定 2 年或更长时间后重新分类为良性或致病性的未知或不确定意义的产前确定的 CNV 的比例。
本研究将建立并跟踪 2013 年至 2019 年期间在澳大利亚维多利亚州进行过染色体微阵列产前诊断的母婴对队列。将使用经过验证的、适合年龄的测量方法对 12 个月至 7 岁的儿童进行评估。主要结局测量指标将是韦氏学前和小学智力量表第四版(WPSSI-IV)智商评分(2.5 至 7 岁)、年龄和阶段问卷(12-30 个月)和婴儿-幼儿社交和情感评估简要版(BITSEA)评分。还将由儿科医生进行临床评估。次要结局将是从以下方面获得的评分:适应行为量表、产后母婴依恋问卷、易受伤害儿童量表、心境状态量表、家长感知能力量表。将对≥2 年后 CNV 再分类率进行描述性分析。
本研究方案描述了澳大利亚首例在染色体微阵列产前诊断后对儿童进行随访的队列研究。它将提供胎儿基因组变异的长期结局,以指导基于证据的产前和产后护理。这反过来又将为减轻怀孕期间传递基因组不确定性的负面影响的未来努力提供信息。
ACTRN12620000446965p;注册于 2020 年 4 月 6 日。